Advanced Accelerator Applications Announces Health Canada Approval for Lutathera™, a Treatment for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

21st European Congress of Endocrinology (ECE)

32nd Annual Congress of the European Association of Nuclear Medicine (EANM)

2019 Multidisciniplary NET Disease Symposium

North American Neuroendocrine Tumor Society (NANETS)

ESMO 2019 Annual Congress

European Society for Medical Oncology (ESMO)

2019 SNMMI Annual Meeting

Society of Nuclear Medicine and Medical Imaging (SNMMI)

2019 ASCO Annual Meeting

American Society of Clinical Oncology (ASCO)

Novartis successfully completes acquisition of Endocyte

Novartis today announced that it has completed the acquisition of Endocyte, Inc., a US-based biopharmaceutical company focused on developing radioligand and CAR-T therapies for cancer treatment.

XIV Congresso Nazionale AIMN

Italian Association for Nuclear Medicine (AIMN)

Advanced Accelerator Applications signs exclusive option and license agreement with FUJIFILM Toyama Chemical to develop and commercialize radiolabeled FF-10158 for oncology indications

AAA today announced that it has entered into an exclusive option and license agreement with FUJIFILM Toyama Chemical, a leading radiopharmaceutical company in Japan, to develop and commercialize radiolabeled FF-10158 for oncology indications.